|
US5585481A
(en)
|
1987-09-21 |
1996-12-17 |
Gen-Probe Incorporated |
Linking reagents for nucleotide probes
|
|
US5378825A
(en)
|
1990-07-27 |
1995-01-03 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs
|
|
JP3131222B2
(ja)
|
1991-12-24 |
2001-01-31 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
ギャップを有する２′修飾オリゴヌクレオチド
|
|
JPH10500310A
(ja)
|
1994-05-19 |
1998-01-13 |
ダコ アクティーゼルスカブ |
淋菌及びトラコーマ クラミジアの検出のためのｐｎａ プローブ
|
|
WO2014093655A2
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
|
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
|
DK2931891T3
(da)
|
2012-12-17 |
2019-08-19 |
Harvard College |
Rna-styret modificering af menneskelige genomer
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
US20150376586A1
(en)
|
2014-06-25 |
2015-12-31 |
Caribou Biosciences, Inc. |
RNA Modification to Engineer Cas9 Activity
|
|
CN106794141B
(zh)
|
2014-07-16 |
2021-05-28 |
诺华股份有限公司 |
将核酸包封在脂质纳米粒主体中的方法
|
|
KR20230156800A
(ko)
|
2015-03-03 |
2023-11-14 |
더 제너럴 하스피탈 코포레이션 |
변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제
|
|
CN107921148A
(zh)
*
|
2015-05-08 |
2018-04-17 |
哈佛学院校长同事会 |
通用供体干细胞和相关方法
|
|
WO2017093969A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
WO2017136794A1
(en)
|
2016-02-03 |
2017-08-10 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
LT3436077T
(lt)
|
2016-03-30 |
2025-06-25 |
Intellia Therapeutics, Inc. |
Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams
|
|
WO2018073393A2
(en)
*
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
SG10202106058WA
(en)
|
2016-12-08 |
2021-07-29 |
Intellia Therapeutics Inc |
Modified guide rnas
|
|
EP4029943A1
(en)
|
2017-05-08 |
2022-07-20 |
Precision Biosciences, Inc. |
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
|
|
CA3064000A1
(en)
*
|
2017-05-24 |
2018-11-29 |
Effector Therapeutics, Inc. |
Methods and compositions for cellular immunotherapy
|
|
WO2019147805A2
(en)
|
2018-01-26 |
2019-08-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Regulatory t cells targeted with chimeric antigen receptors
|
|
US11447769B2
(en)
|
2018-03-27 |
2022-09-20 |
The Trustees Of The University Of Pennsylvania |
Modified immune cells having enhanced function and methods for screening for same
|
|
AU2019282824C1
(en)
|
2018-06-08 |
2026-04-23 |
Intellia Therapeutics, Inc. |
Modified guide RNAS for gene editing
|
|
EP3581200A1
(en)
|
2018-06-13 |
2019-12-18 |
GEMoaB Monoclonals GmbH |
Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
CN113227374A
(zh)
|
2018-10-16 |
2021-08-06 |
因特利亚治疗公司 |
用于免疫疗法的组合物和方法
|
|
WO2020092057A1
(en)
|
2018-10-30 |
2020-05-07 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
|
EP3969041A4
(en)
*
|
2019-05-14 |
2023-05-10 |
Taiga Biotechnologies, Inc. |
COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION
|
|
CA3181340A1
(en)
|
2020-04-28 |
2021-11-04 |
Intellia Therapeutics, Inc. |
Methods of in vitro cell delivery
|